This article examines the growing importance of certifications as a defining standard in pharmaceutical logistics. As regulatory scrutiny intensifies and supply chains become more complex, certifications signal a provider’s ability to meet stringent quality, compliance, and handling requirements. From GDP compliance and specialized training to validated processes and audit readiness, explore how certified logistics partners go beyond basic visibility tools to deliver trust, accountability, and risk mitigation. The piece also highlights how shippers can evaluate partners based on credentials that ensure consistent performance and safeguard sensitive pharmaceutical products throughout the supply chain.
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.
Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth up to $1.5 billion for berobenatide, and Parexel’s Stacy Hurt on how patients’ use of AI is reshaping sponsor communication.
Pfizer and Blackstone Life Sciences sign a co-funding deal in which Blackstone is set to provide up to $1.5 billion through 2028 to advance berobenatide.
